It was a prospective three-armed, single-blinded randomized controlled trial (RCT) conducted at a university hospital in Norway. 104 patients who had at least one migraine attack per month were studied over a period of 17 months. The control group continued with their usual pharmacological management, the active treatment group got SMT, and the placebo group got “a sham push maneuver of the lateral edge of the scapula and/or the gluteal region.” I would have thought patients could tell the difference, but they couldn’t. The blinding was successful. They did an “exit poll” after each intervention session, and more than 80% of subjects in both the active treatment and the placebo treatment groups believed they had received SMT.
No comments:
Post a Comment